Twinbeech Capital LP Has $2.26 Million Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Twinbeech Capital LP lessened its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 44.9% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 87,802 shares of the company’s stock after selling 71,664 shares during the quarter. Twinbeech Capital LP’s holdings in IDEAYA Biosciences were worth $2,257,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. R Squared Ltd acquired a new stake in shares of IDEAYA Biosciences in the fourth quarter valued at approximately $35,000. Daiwa Securities Group Inc. raised its stake in IDEAYA Biosciences by 44.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company’s stock valued at $72,000 after acquiring an additional 853 shares during the period. KBC Group NV lifted its holdings in IDEAYA Biosciences by 84.6% during the 4th quarter. KBC Group NV now owns 4,197 shares of the company’s stock valued at $108,000 after purchasing an additional 1,923 shares during the last quarter. Cibc World Markets Corp bought a new position in IDEAYA Biosciences during the fourth quarter worth $203,000. Finally, Mariner LLC boosted its position in IDEAYA Biosciences by 9.8% during the fourth quarter. Mariner LLC now owns 9,775 shares of the company’s stock worth $251,000 after purchasing an additional 869 shares during the period. Institutional investors and hedge funds own 98.29% of the company’s stock.

Analyst Ratings Changes

Separately, Stephens reissued an “overweight” rating and issued a $50.00 price objective on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Two investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, IDEAYA Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $54.27.

IDEAYA Biosciences Price Performance

IDYA stock opened at $19.15 on Thursday. IDEAYA Biosciences, Inc. has a fifty-two week low of $13.45 and a fifty-two week high of $44.42. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of -5.80 and a beta of 0.26. The business’s fifty day moving average price is $17.66 and its two-hundred day moving average price is $22.07.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter last year, the business posted ($0.53) EPS. Research analysts expect that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.